Virbac Dividendi e riacquisti
Criteri Dividendo verificati 0/6
Virbac è una società che paga dividendi con un rendimento attuale di 0.4%.
Informazioni chiave
0.4%
Rendimento del dividendo
n/a
Rendimento del riacquisto
| Rendimento totale per gli azionisti | n/a |
| Rendimento futuro dei dividendi | 0.7% |
| Crescita dei dividendi | -1.5% |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | 8% |
Aggiornamenti recenti su dividendi e riacquisti
Recent updates
Aggiornamento della narrazione • May 24
VIRP: Stable Margins And P/E Assumptions Will Support Future Upside Repricing
Analysts have made a very small adjustment to Virbac's fair value estimate, nudging the price target from €413.00 to around €412.88. This reflects updated fine tuning of revenue growth, profit margin and future P/E assumptions.Aggiornamento della narrazione • May 09
VIRP: Human Animal Bond Partnership Will Support Future Upside Repricing
Analysts have made a small upward adjustment to their Virbac target, lifting fair value from about €412.33 to €413.00. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.Aggiornamento della narrazione • Mar 11
VIRP: Human Animal Bond Partnership Will Support 2026 Outlook Repricing
Analysts have made a small adjustment to their Virbac price target to reflect marginal tweaks in fair value, growth and margin assumptions, trimming it by about €0.50 to €412.33. What's in the News Virbac entered a new partnership with the Human Animal Bond Research Institute to support efforts that strengthen the human animal bond and its impact on companion animal and human health, focusing on science, education and collaboration (Key Developments).Aggiornamento della narrazione • Feb 25
VIRP: Stable Assumptions And 2026 Guidance Will Support Bullish Repricing
Analysts have maintained their Virbac price target at €412.82, indicating unchanged views on fair value, discount rate, growth assumptions, and margin expectations for the company. What's in the News Virbac entered a partnership with the Human Animal Bond Research Institute (HABRI) to support efforts that strengthen the human animal bond and its impact on companion animal and human health, with a focus on science, education and collaboration (Key Developments).Aggiornamento della narrazione • Feb 11
VIRP: Stable Inputs And 2026 Guidance Will Support Bullish Repricing
Analysts have kept Virbac's fair value estimate steady at €412.82 per share, with only small technical adjustments to inputs such as the discount rate and assumed future P/E informing this unchanged price target. What's in the News Virbac issued earnings guidance for 2026, including the impact of the Thyronorm acquisition, with revenue growth expected to be between 5.5% and 7.5% at constant rates and scope (Key Developments).Aggiornamento della narrazione • Jan 26
VIRP: Broad Regional Execution And 2026 Outlook Will Support Bullish Repricing
Narrative Update The analyst price target for Virbac has been raised from €390 to €415, with analysts citing accelerated growth across all regions as the key driver of this change. Analyst Commentary Analysts lifting their price target on Virbac to €415 from €390 are focusing on how the company is executing its growth plans across regions and what that could mean for valuation and risk.Aggiornamento della narrazione • Jan 07
VIRP: Broad Regional Acceleration Will Support Upgraded Buy Rating Into 2025
Narrative Update on Virbac Analysts have increased their price target on Virbac to €415 from €390, citing what they describe as accelerated growth across all regions as the key driver for their updated view. Analyst Commentary Recent research points to a more constructive stance on Virbac, with analysts raising their price target to €415 from €390 as they reassess the company’s growth profile.Aggiornamento della narrazione • Dec 23
VIRP: Broad Regional Acceleration Will Sustain Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac from EUR 390 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to a higher price target as a reflection of stronger than expected execution in scaling operations across all regions.Aggiornamento della narrazione • Dec 09
VIRP: Broad Regional Momentum Will Support Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac by EUR 25 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Following the recent upgrade, research coverage has focused on the sustainability of Virbac’s growth acceleration and its implications for valuation.Aggiornamento della narrazione • Nov 25
VIRP: Accelerated Regional Momentum Will Sustain an Upgraded Bullish Outlook for 2025
Analysts have raised Virbac's price target from €390 to €415, citing accelerated growth across all regions as the key driver for their more positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts cite a clear acceleration in Virbac's growth across all geographic regions, which supports a more positive outlook for the company.Aggiornamento della narrazione • Nov 07
VIRP: Accelerated Regional Expansion Will Drive Upgraded Earnings Outlook Next Year
Narrative Update on Virbac Analysts have raised Virbac's price target from €398 to €403, citing accelerated growth across all regions as the primary driver for this upward revision. Analyst Commentary The most recent research notes reflect increased optimism around Virbac's trajectory, with upward revisions to both rating and price targets.Articolo di analisi • Oct 05
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Key Insights Virbac's estimated fair value is €563 based on 2 Stage Free Cash Flow to Equity Virbac's €323 share price...Articolo di analisi • Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Shareholders might have noticed that Virbac SA ( EPA:VIRP ) filed its quarterly result this time last week. The early...Articolo di analisi • Aug 30
There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 19.3x might make it look like a sell right now compared...Articolo di analisi • Jun 23
Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?
Key Insights Virbac's estimated fair value is €601 based on 2 Stage Free Cash Flow to Equity Virbac's €324 share price...Articolo di analisi • May 18
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 15x, you may consider...Articolo di analisi • Apr 30
Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Nuova narrazione • Mar 16
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.Articolo di analisi • Jan 24
Earnings Not Telling The Story For Virbac SA (EPA:VIRP)
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 17.9x might make it look like a sell right now compared...Articolo di analisi • Oct 06
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Key Insights The projected fair value for Virbac is €699 based on 2 Stage Free Cash Flow to Equity Virbac is estimated...Articolo di analisi • Sep 18
Virbac SA Just Beat Revenue Estimates By 6.0%
It's been a good week for Virbac SA ( EPA:VIRP ) shareholders, because the company has just released its latest...Articolo di analisi • Aug 31
Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
With a price-to-earnings (or "P/E") ratio of 24x Virbac SA ( EPA:VIRP ) may be sending very bearish signals at the...Articolo di analisi • Jun 15
Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Key Insights Virbac's Annual General Meeting to take place on 21st of June Salary of €379.0k is part of CEO Sebastien...Articolo di analisi • Jun 10
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Virbac fair value estimate is €551 Virbac's €363 share price...Articolo di analisi • May 21
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
With a price-to-earnings (or "P/E") ratio of 24.2x Virbac SA ( EPA:VIRP ) may be sending bearish signals at the moment...Articolo di analisi • Mar 22
Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Last week saw the newest yearly earnings release from Virbac SA ( EPA:VIRP ), an important milestone in the company's...Articolo di analisi • Jan 18
Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Key Insights The projected fair value for Virbac is €440 based on 2 Stage Free Cash Flow to Equity Virbac's €340 share...Articolo di analisi • Dec 27
Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Virbac SA ( EPA:VIRP ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking...Articolo di analisi • Oct 19
Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Sep 26
Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Key Insights Virbac's estimated fair value is €411 based on 2 Stage Free Cash Flow to Equity Current share price of...Articolo di analisi • Sep 05
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Jun 20
A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Key Insights The projected fair value for Virbac is €337 based on 2 Stage Free Cash Flow to Equity Current share price...Articolo di analisi • May 31
Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Apr 09
Is Virbac (EPA:VIRP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Feb 28
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights The projected fair value for Virbac is €437 based on 2 Stage Free Cash Flow to Equity Virbac's €288 share...Articolo di analisi • Nov 25
Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...Articolo di analisi • Oct 14
Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Articolo di analisi • Aug 07
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...Articolo di analisi • Jun 26
These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • May 01
Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Articolo di analisi • Mar 26
We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Jan 26
Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Articolo di analisi • Dec 28
Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Articolo di analisi • Oct 27
A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Does the October share price for Virbac SA ( EPA:VIRP ) reflect what it's really worth? Today, we will estimate the...Articolo di analisi • Oct 12
Is Virbac (EPA:VIRP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: VIRP non sta pagando un dividendo degno di nota per il mercato French, pertanto non è necessario verificare se i pagamenti sono stabili.
Dividendo in crescita: VIRP non sta pagando un dividendo degno di nota per il mercato French, pertanto non è necessario verificare se i pagamenti stanno aumentando.
Rendimento dei dividendi rispetto al mercato
| Virbac Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (VIRP) | 0.4% |
| Fondo del 25% del mercato (FR) | 2.0% |
| Top 25% del mercato (FR) | 5.6% |
| Media del settore (Pharmaceuticals) | 4.7% |
| Analista previsionale (VIRP) (fino a 3 anni) | 0.7% |
Dividendo notevole: Il dividendo di VIRP ( 0.4% ) non è degno di nota rispetto al 25% inferiore dei pagatori di dividendi nel mercato French ( 1.97% ).
Dividendo elevato: Il dividendo di VIRP ( 0.4% ) è basso rispetto al 25% dei maggiori pagatori di dividendi nel mercato French ( 5.56%.
Distribuzione degli utili agli azionisti
Copertura degli utili: VIRP non sta pagando un dividendo degno di nota per il mercato French.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: VIRP non sta pagando un dividendo degno di nota per il mercato French.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/29 22:22 |
| Prezzo dell'azione a fine giornata | 2026/05/29 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Virbac SA è coperta da 12 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Delphine Le Louet | Bernstein |
| Laurent Gelebart | BNP Paribas |
| Arnaud Cadart | CIC Market Solutions (ESN) |